JAMA Neurol: Benign prostate hyperplies may prevent Parkinson's disease

Parkinson's disease (PD) is a common neurodegenerative disease that currently affects about 10 million people worldwide and is growing rapidly as the population ages.
PD patients have a variety of manifestations, including motor and cognitive symptoms.
commonly used treatments, such as L-Doba and brain stimulation, can improve the motor symptoms of PD patients, but will not alleviate the process of sexual neurodegeneration.
in animal models and early clinical studies, the efficacy of enhanced glycolysis and inhibition of PD progression in patients was shown.
researchers recently examined the preventive effects of tragin, polysalazole and alfalgam on PD. The
study, conducted in Denmark and collecting data on male patients who had no PD symptoms on the baseline but who had received the first treatment of tracostazine/dosazine/aphdoline or tanlo for benign prostate hyperplus or unsealed urinary system symptoms, began in 1996 and the data analysis continued until July 2020.
of the study was the risk of PD in patients who received pyridol compared to those who received tannins.
Danish queue collected data on 52,365 male patients, with an average age of 67.9 years, while the Truven database collected data on 94,883 male patients, with an average age of 63.8 years.
compared to patients receiving new treatment with tanlo, the PD risk (HR) in patients receiving tracosin/dosazine/avonol in the Danish queue was 0.88, compared to 0.63 in the Truven queue.
in the Danish queue, patients received tracophospheric/dosazine/avonazine treatment with P in the short term (0.95), medium term (0.88) or long-term (0.79) There was a dose correlation to the reduction in the risk of D, and the Truven queue (short-term: HR=0.70; medium-term: HR=0.58; long-term: HR=0.46) showed similar results.
study found that in patients with benign prostate hyperplosomes, parkinson's risk decreased in people treated with pyridone.